Nuveen Asset Management LLC Acquires 65,713 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Nuveen Asset Management LLC boosted its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 14.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 529,650 shares of the company's stock after purchasing an additional 65,713 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.42% of Vaxcyte worth $43,357,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. CIBC Asset Management Inc boosted its holdings in shares of Vaxcyte by 5.5% in the fourth quarter. CIBC Asset Management Inc now owns 3,307 shares of the company's stock worth $271,000 after buying an additional 171 shares during the last quarter. Bridgefront Capital LLC grew its position in Vaxcyte by 4.2% in the fourth quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock worth $347,000 after acquiring an additional 172 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after purchasing an additional 260 shares during the period. Catalyst Funds Management Pty Ltd boosted its holdings in Vaxcyte by 1.7% during the 4th quarter. Catalyst Funds Management Pty Ltd now owns 18,400 shares of the company's stock valued at $1,506,000 after acquiring an additional 300 shares during the period. Finally, Whipplewood Advisors LLC purchased a new stake in Vaxcyte in the 4th quarter valued at about $28,000. Institutional investors own 96.78% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on PCVX shares. Guggenheim reissued a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a research report on Wednesday, March 12th. The Goldman Sachs Group cut their price objective on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Bank of America lowered their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Finally, Needham & Company LLC reissued a "buy" rating and issued a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $136.50.

Insider Buying and Selling at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares of the company's stock, valued at approximately $11,351,794.37. This trade represents a 4.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Trading Up 0.6%

Shares of PCVX stock opened at $32.03 on Tuesday. The company has a market cap of $4.13 billion, a PE ratio of -6.96 and a beta of 1.27. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06. The company's fifty day simple moving average is $41.73 and its 200-day simple moving average is $70.94.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the prior year, the company earned ($0.85) EPS. Equities research analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.